MRNA Stock — Moderna Inc.: Cash, EV, Pipeline

Share price

$154.04

Market cap

$61,498.3M

Cash

$5,138.0M

Enterprise value

$56,951.3M

Balance sheet

Cash	$5,138.0M
Debt	$591.0M
Net cash	$4,547.0M
Enterprise value	$56,951.3M
Basic shares	399.0M shares
Fully diluted shares	399.2M shares
Fully diluted market cap	$61,498.3M
Cash per share	$12.88

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading MRNA daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Nov 3 - Dec 15	mRNA-1403	Phase 2	Norovirus Acute Gastroenteritis	—
Nov 16 - Dec 28	mRNA-1189	Phase 2	Epstein-Barr Virus Infection	—
Nov 24, 2026 - Jan 5, 2027	mRNA-1195.1	Phase 1	Epstein-Barr Virus Infection	—
Jan 11 - Feb 22	mRNA-3745	Phase 2	Glycogen Storage Disease	—
Jan 19 - Mar 2	mRNA-1645-eODGT8	Phase 1	HIV Infections	—
Jan 27 - Mar 10	mRNA-0184	Phase 1	Healthy Participants	—
Mar 11 - Apr 22	mRNA-1018-H5	Phase 3	Influenza	—
Mar 29 - May 10	mRNA-1403	Phase 3	Acute Gastroenteritis; Norovirus Acute Gastroenteritis	—
Apr 17 - May 29	mRNA-1647	Phase 2	Cytomegalovirus Infection	—
Jun 4 - Jul 16	Pembrolizumab	Phase 2	Bladder Cancer	—
Jun 26 - Aug 7	mRNA-1189	Phase 1	Epstein-Barr Virus	—
Aug 31 - Oct 12	mRNA-1365 (Profile 2)	Phase 1	Respiratory Syncytial Virus (RSV); Human Metapneuomovirus (hMPV)	—
Sep 14 - Oct 26	mRNA-4106	Phase 1	Advanced Solid Tumors	—
Oct 12 - Nov 23	mRNA-3927	Phase 2	Propionic Acidemia	—
Nov 11 - Dec 23	mRNA-1469	Phase 1	Ebola-Bundibugyo Virus Disease (Ebola-BDBV)	—
Jan 2 - Feb 13	mRNA-4157	Phase 1	Solid Tumors	—
Feb 19 - Apr 1	Intismeran autogene	Phase 2	Renal Cell Carcinoma	—
Dec 21, 2028 - Feb 1, 2029	mRNA-1982	Phase 2	Lyme Disease	—
Feb 19 - Apr 2	mRNA-1195	Phase 2	Multiple Sclerosis	—
Aug 13 - Sep 24	Intismeran Autogene	Phase 2	Squamous Non-small Cell Lung Cancer	—
Sep 12 - Oct 24	IMA203	Phase 1	Cutaneous Melanoma; Synovial Sarcoma	—
Oct 11 - Nov 22	mRNA-1283	Phase 2	SARS-CoV-2	—
Oct 12 - Nov 23	mRNA-1345	Phase 1	Respiratory Syncytial Virus; Human Metapneumovirus	—
Jan 15 - Feb 26	mRNA-3927	Phase 2	Propionic Acidemia	—
Jul 29 - Sep 9	mRNA-2808	Phase 2	Relapsed or Refractory Multiple Myeloma	—
Aug 6 - Sep 17	Intismeran autogene	Phase 3	Non-small Cell Lung Cancer	—
Oct 15 - Nov 26	Intismeran autogene	Phase 2	Urinary Bladder Neoplasms; Non-Muscle Invasive Bladder Neoplasms; Carcinoma in Situ	—
Mar 31 - May 12	mRNA-4359	Phase 2	Advanced Solid Tumors	—
Jan 2 - Feb 13	mRNA-4157	Phase 2	Melanoma	—
Jun 27 - Aug 8	Pembrolizumab	Phase 3	Carcinoma, Non-Small-Cell Lung	—
May 14 - Jun 25	mRNA-3705	Phase 2	Methylmalonic Acidemia	—
Oct 3 - Nov 14	Intismeran	Phase 3	Non-small Cell Lung Cancer	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

Spikevax

Approved · Active Modality: mRNA vaccine

Indications

COVID-19 (Approved)

Status note Approved COVID vaccine.

mNEXSPIKE

Approved · Active Modality: mRNA vaccine

Target SARS-CoV-2 spike

Indications

COVID-19 (Approved)

Status note Approved COVID vaccine for adults 65+ and adults 12-64 with underlying risk factors; commercial sales launched Q3 2025.

mRESVIA

Approved · Active Modality: mRNA vaccine

Target RSV F protein

Indications

Respiratory syncytial virus (Approved)

Status note Approved RSV vaccine for older adults and high-risk adults ages 18-59.

mCOMBRIAX

Approved · Active Modality: mRNA vaccine

Aliases mRNA-1083

Target influenza HA + SARS-CoV-2 spike

Indications

Influenza + COVID-19 (Approved)

Status note Approved by European Commission (Apr 2026) for influenza + COVID-19 in adults 50+; not yet commercialized as of Jun 30, 2026.

mRNA-1010

Phase 3 · Active Modality: mRNA vaccine

Target influenza HA proteins

Indications

Seasonal influenza (Phase 3)

Catalysts

— August 5, 2026

Status note Seasonal influenza vaccine candidate. BLA accepted for review (amended application after prior refusal-to-file); VRBPAC voted unanimously benefits outweigh risks (Jun 2026); filings also under review in Europe, Canada, Australia.

mFLUSIVA

Stage not disclosed · Active

Indications

Seasonal influenza (Stage not disclosed)

Status note Filing references potential near-term approval of mFLUSIVA; no stage or code detail in excerpts.

mRNA-4157

Phase 3 · Active Modality: mRNA individualized neoantigen therapy

Aliases intismeran autogene

Target patient-specific neoantigens

Partnerships Merck (2016 collaboration & license; costs/profits shared ~equally; Merck leads clinical trials)

Indications

Melanoma (adjuvant) (Phase 3)
NSCLC (high-risk Stage 1) (Phase 3)
Bladder cancer (Phase 2)
Renal cell carcinoma (Phase 2)

Catalysts

— 2026

Status note Individualized neoantigen therapy (generic: intismeran autogene). Nine Phase 2/3 trials across melanoma, NSCLC, bladder cancer, RCC, including Phase 3 monotherapy/+KEYTRUDA QLEX in high-risk Stage 1 NSCLC.

mRNA-1403

Phase 3 · Active Modality: mRNA vaccine

Target norovirus (GI/GII genotypes)

Indications

Norovirus (Phase 3)

Status note Norovirus vaccine Phase 3 study; enrollment of second Northern Hemisphere (2025-2026) cohort completed.

mRNA-3927

Phase 3 · Active Modality: mRNA therapeutic

Target PCCA + PCCB

Partnerships Recordati (Jan 2026 collaboration; exclusive worldwide license; Moderna leads clinical development through approval; Recordati leads commercialization)

Indications

Propionic acidemia (Phase 3)

Catalysts

— 2026

Status note Investigational propionic acidemia therapeutic in registrational study; target enrollment reached.

mRNA-4359

Phase 1 · Active Modality: mRNA cancer antigen therapy

Target IDO + PD-L1

Indications

Metastatic melanoma (Phase 1)
Metastatic NSCLC (Phase 1)

Status note Wholly-owned investigational cancer antigen therapy; Phase 1/2 study ongoing with cohorts in 1L/2L+ metastatic melanoma and 1L metastatic NSCLC.

Per-asset detail extracted from the 10-Q filed 2026-07-31. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	mRNA-1018-H5
Lead indication	Influenza
Lead phase	Phase 3
Active trials	28
Collaborator trials	14

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07496450	Phase 3	Active, not recruiting	Sponsor	MRNA	—	Influenza	—
NCT06592794	Phase 3	Active, not recruiting	Sponsor	MRNA	—	Acute Gastroenteritis; Norovirus Acute Gastroenteritis	—
NCT05992935	Phase 2	Active, not recruiting	Sponsor	MRNA	—	Norovirus Acute Gastroenteritis	—
NCT05164094	Phase 2	Active, not recruiting	Sponsor	MRNA	—	Epstein-Barr Virus Infection	—
NCT05095727	Phase 2	Active, not recruiting	Sponsor	MRNA	—	Glycogen Storage Disease	—
NCT05683457	Phase 2	Active, not recruiting	Sponsor	MRNA	—	Cytomegalovirus Infection	—
NCT04159103	Phase 2	Recruiting	Sponsor	MRNA	—	Propionic Acidemia	—
NCT07561294	Phase 2	Active, not recruiting	Sponsor	MRNA	—	Lyme Disease	—
NCT06735248	Phase 2	Recruiting	Sponsor	MRNA	—	Multiple Sclerosis	—
NCT07808697	Phase 2	Not yet recruiting	Sponsor	MRNA	—	SARS-CoV-2	—
NCT05130437	Phase 2	Recruiting	Sponsor	MRNA	—	Propionic Acidemia	—
NCT07116616	Phase 2	Recruiting	Sponsor	MRNA	—	Relapsed or Refractory Multiple Myeloma	—

Sponsor-matched active trials from ClinicalTrials.gov (28 as sponsor, 14 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 42 active trials for ModernaTX, Inc. on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

MRNA — Moderna Inc.

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials